Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre
Éamon P McCarron(Salford Royal NHS Foundation Trust), Ana Jovanović(Manchester Academic Health Science Centre), Peter Woolfson(Salford Royal NHS Foundation Trust), Reena Sharma(Salford Royal NHS Foundation Trust), Rajkumar Chinnadurai(Salford Royal NHS Foundation Trust), Karolina M. Stępień(Salford Royal NHS Foundation Trust), Jonathan M. Meyer(Salford Royal NHS Foundation Trust), Thomas L. Anderson(American Heart Association)
Cited by 7
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345
Statin-induced myopathies
|Pharmacological Reports|2011|206
Patients' Self-Assessed Functional Status in Heart Failure by New York Heart Association Class: A Prognostic Predictor of Hospitalizations, Quality of Life and Death
|Journal of Cardiac Failure|2009|161
Evidence of Oxidative Stress and Secondary Mitochondrial Dysfunction in Metabolic and Non-Metabolic Disorders
|Journal of Clinical Medicine|2017|148